title: [Efficacy of zoledronic acid for osteoporosis:evidence from studies abroad.]
abstract: Zoledronic acid is a nitrogen-containing bisphosphonate that has the strongest and the most persistent anti-resorptive activity. Once-yearly zoledronic acid has recently been approved for the treatment of osteoporosis in Japan. This overview summarizes abundant evidence of zoledronic acid, obtained from studies abroad, for its efficacy for postmenopausal, male and glucocorticoid-induced osteoporosis.
authors.affiliation: Third Department of Medicine, Teikyo University Chiba Medical Center, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Inoue
mesh_terms: D015415:Biomarkers / Q000032:analysis; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D055502:Secondary Prevention; D000077211:Zoledronic Acid
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid